The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Prolactinoma


Psychiatry related information on Prolactinoma


High impact information on Prolactinoma


Chemical compound and disease context of Prolactinoma


Biological context of Prolactinoma


Anatomical context of Prolactinoma


Gene context of Prolactinoma


Analytical, diagnostic and therapeutic context of Prolactinoma


  1. Dopamine agonists and pituitary tumor shrinkage. Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F. Endocr. Rev. (1992) [Pubmed]
  2. Acromegaly and galactorrhea-amenorrhea with two pituitary adenomas secreting growth hormone or prolactin. A case report. Tolis, G., Bertrand, G., Carpenter, S., McKenzie, J.M. Ann. Intern. Med. (1978) [Pubmed]
  3. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. Petty, E.M., Green, J.S., Marx, S.J., Taggart, R.T., Farid, N., Bale, A.E. Am. J. Hum. Genet. (1994) [Pubmed]
  4. Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules. Saitoh, Y., Mori, S., Arita, N., Hayakawa, T., Mogami, H., Matsumoto, K., Mori, H. Cancer Res. (1986) [Pubmed]
  5. Pituitary tumors in mice exposed prenatally to diethylstilbestrol. Walker, B.E., Kurth, L.A. Cancer Res. (1993) [Pubmed]
  6. Hyperprolactinemia in two patients with eating disorders. Casper, R.C., Douglas, Z., Staples, N. The Journal of clinical psychiatry. (1987) [Pubmed]
  7. Effect of risperidone on prolactinoma--a case report. Mendhekar, D.N., Jiloha, R.C., Srivastava, P.K. Pharmacopsychiatry (2004) [Pubmed]
  8. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Colao, A., De Rosa, M., Sarnacchiaro, F., Di Sarno, A., Landi, M.L., Iervolino, E., Zarrilli, S., Merola, B., Lombardi, G. Eur. J. Endocrinol. (1996) [Pubmed]
  9. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Melkersson, K., Hulting, A.L. European archives of psychiatry and clinical neuroscience. (2000) [Pubmed]
  10. A possible effect of amisulpride on a prolactinoma growth in a woman with borderline personality disorder. Perroud, N., Huguelet, P. Pharmacol. Res. (2004) [Pubmed]
  11. Improvement in headache associated with prolactinoma during treatment with a somatostatin analogue: an "N of 1" study. Williams, G., Ball, J., Bloom, S., Joplin, G.F. N. Engl. J. Med. (1986) [Pubmed]
  12. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. Liuzzi, A., Dallabonzana, D., Oppizzi, G., Verde, G.G., Cozzi, R., Chiodini, P., Luccarelli, G. N. Engl. J. Med. (1985) [Pubmed]
  13. CSF rhinorrhea after bromocriptine for prolactinoma. Baskin, D.S., Wilson, C.B. N. Engl. J. Med. (1982) [Pubmed]
  14. Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors. Sarkar, D.K., Gottschall, P.E., Meites, J. Science (1982) [Pubmed]
  15. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription. Shimon, I., Hüttner, A., Said, J., Spirina, O.M., Melmed, S. J. Clin. Invest. (1996) [Pubmed]
  16. Tests of prolactin secretion in diagnosis of prolactinomas. Cowden, E.A., Ratcliffe, J.G., Thomson, J.A., Macpherson, P., Doyle, D., Teasdale, G.M. Lancet (1979) [Pubmed]
  17. Heterogeneity of prolactin responses to oestradiol benzoate in women with prolactinomas. White, M.C., Anapliotou, M., Rosenstock, J., Mashiter, K., Joplin, G.F. Lancet (1981) [Pubmed]
  18. Reexpression of p8 contributes to tumorigenic properties of pituitary cells and appears in a subset of prolactinomas in transgenic mice that hypersecrete luteinizing hormone. Mohammad, H.P., Seachrist, D.D., Quirk, C.C., Nilson, J.H. Mol. Endocrinol. (2004) [Pubmed]
  19. Lack of demonstrable tumor growth in progressive hyperprolactinemia. Sisam, D.A., Sheehan, J.P., Schumacher, O.P. Am. J. Med. (1986) [Pubmed]
  20. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Finelli, P., Pierantoni, G.M., Giardino, D., Losa, M., Rodeschini, O., Fedele, M., Valtorta, E., Mortini, P., Croce, C.M., Larizza, L., Fusco, A. Cancer Res. (2002) [Pubmed]
  21. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Oka, H., Jin, L., Reubi, J.C., Qian, X., Scheithauer, B.W., Fujii, K., Kameya, T., Lloyd, R.V. Am. J. Pathol. (1998) [Pubmed]
  22. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Missale, C., Losa, M., Sigala, S., Balsari, A., Giovanelli, M., Spano, P.F. Mol. Endocrinol. (1996) [Pubmed]
  23. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Fiorentini, C., Guerra, N., Facchetti, M., Finardi, A., Tiberio, L., Schiaffonati, L., Spano, P., Missale, C. Mol. Endocrinol. (2002) [Pubmed]
  24. Establishment and characterization of a new human cultured cell line from a prolactin-secreting pituitary adenoma. Kikuchi, Y., Seki, K., Momose, E., Kizawa, I., Oomori, K., Shima, K., Mukai, K., Kato, K. Cancer Res. (1985) [Pubmed]
  25. Role of matrix metalloproteinase 9 in pituitary tumor behavior. Turner, H.E., Nagy, Z., Esiri, M.M., Harris, A.L., Wass, J.A. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  26. Circulating fibroblast growth factor-like autoantibodies in two patients with multiple endocrine neoplasia type 1 and prolactinoma. Zimering, M.B., Riley, D.J., Thakker-Varia, S., Walker, A.M., Lakshminaryan, V., Shah, R., Brandi, M.L., Ezzat, S., Katsumata, N., Friesen, H.G. J. Clin. Endocrinol. Metab. (1994) [Pubmed]
  27. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., Lombardi, G. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  28. Angiogenesis in pituitary adenomas and the normal pituitary gland. Turner, H.E., Nagy, Z., Gatter, K.C., Esiri, M.M., Harris, A.L., Wass, J.A. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  29. Development and potential clinical uses of human prolactin receptor antagonists. Goffin, V., Bernichtein, S., Touraine, P., Kelly, P.A. Endocr. Rev. (2005) [Pubmed]
  30. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Shimon, I., Yan, X., Taylor, J.E., Weiss, M.H., Culler, M.D., Melmed, S. J. Clin. Invest. (1997) [Pubmed]
  31. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. Schuff, K.G., Hentges, S.T., Kelly, M.A., Binart, N., Kelly, P.A., Iuvone, P.M., Asa, S.L., Low, M.J. J. Clin. Invest. (2002) [Pubmed]
  32. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Paez-Pereda, M., Giacomini, D., Refojo, D., Nagashima, A.C., Hopfner, U., Grubler, Y., Chervin, A., Goldberg, V., Goya, R., Hentges, S.T., Low, M.J., Holsboer, F., Stalla, G.K., Arzt, E. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  33. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Williams, J.C., Stone, D., Smith-Arica, J.R., Morris, I.D., Lowenstein, P.R., Castro, M.G. Mol. Ther. (2001) [Pubmed]
  34. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors. Ishibashi, M., Yamaji, T., Takaku, F., Teramoto, A., Fukushima, T. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  35. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Jaquet, P., Ouafik, L., Saveanu, A., Gunz, G., Fina, F., Dufour, H., Culler, M.D., Moreau, J.P., Enjalbert, A. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  36. Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER alpha and a tumor-specific splice variant. Chaidarun, S.S., Swearingen, B., Alexander, J.M. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
WikiGenes - Universities